Table 3.
Frailty assessment using Vigorito et al.’s tool.
| CORO | PCI | CABG | HF | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| M (n = 14) | F (n = 13) | M (n = 19) | F (n = 11) | M (n = 14) | F (n = 2) | M (n = 29) | F (n = 31) | |||
| MNA | NF/MiF/ModF/SF | n | 10/3/1/0 | 9/3/1/0 | 16/3/0/0 | 8/2/1/0 | 7/5/2/0 | 0/2/0/0 | 9/15/5/0 | 4/16/7/4 |
| % | 71.4/21.4/7.1/0.0 | 69.2/23.1/7.7/0.0 | 84.2/15.8/0.0/0.0 | 72.7/18.2/9.1/0.0 | 50.0/35.7/14.3 | 0.0/100/0.0/0.0 | 31.0/51.7/17.2/0.0 | 12.9/51.6/22.6/12.9 | ||
| Katz independence in ADL | NF/MiF/ModF/SF | n | 12/2/0/0 | 10/3/0/0 | 19/0/0/0 | 11/0/0/0 | 11/3/0/0 | 2/0/0/0 | 19/6/4/0 | 17/12/2/0 |
| % | 85.7/14.3/0.0/0.0 | 76.9/23.1/0.0/0.0 | 100/0.0/0.0/0.0 | 100/0.0/0.0 | 78.6/21.4/0.0/0.0 | 100/0.0/0.0/0.0 | 65.5/20.7/13.8/0.0 | 54.8/38.7/6.5/0.0 | ||
| Gait speed | NF/MiF/ModF/SF | n | 11/2/0/1 | 6/3/4/0 | 17/2/0/0 | 10/1/0/0 | 8/1/4/1 | 0/1/0/1 | 7/5/7/10 | 5/2/14/10 |
| % | 78.6/14.3/0.0/7.1 | 46.2/23.1/30.8/0.0 | 89.5/10.5/0.0/0.0 | 90.9/9.1/0.0/0.0 | 57.1/7.1/28.6/7.1 * | 0.0/50.0/0.0/50.0 | 24.1/17.2/24.1/34.5 | 16.1/6.5/45.2/32.3 | ||
| TUG | NF/MiF/ModF/SF | n | 11/2/0/1 | 6/2/4/1 | 17/2/0/0 | 8/2/1/0 | 8/2/3/1 | 1/0/0/1 | 6/5/8/10 | 6/6/10/9 |
| % | 78.6/14.3/0.0/7.1 | 46.2/15.4/30.8/7.7 | 89.5/10.5/0.0/0.0 | 72.7/18.2/9.1/0.0 | 57.1/14.3/21.4/7.1 | 50.0/0.0/0.0/50.0 | 20.7/17.2/27.6/34.5 | 19.4/19.4/32.3/29.0 | ||
| Handgrip strength | NF/MiF/ModF/SF | n | 11/1/1/1 | 13/0/0/0 | 14/3/2/0 | 10/1/0/0 | 10/2/1/1 | 1/1/0/0 | 9/8/10/2 | 14/7/9/1 |
| % | 78.6/7.1/7.1/71 | 100/0.0/0.0/0.0 | 73.7/15.8/10.5/0.0 | 90.9/9.1/0.0/0.0 | 71.4/14.3/7.1/7.1 | 50.0/50.0/0.0/0.0 | 31.0/27.6/34.5/6.9 | 45.2/22.6/29.0/3.2 | ||
| MMSE | NF/MiF/ModF/SF | n | 13/1/0/0 | 10/2/1/0 | 19/0/0/0 | 11/0/0/0 | 13/0/0/1 | 2/0/0/0 | 16/11/2/0 | 22/5/3/1 |
| % | 92.9/7.1/0.0/0.0 | 76.9/15.4/7.7/0.0 | 100/0.0/0.0/0.0 | 100/0.0/0.0/0.0 | 92.9/0.0/0.0/7.1 | 100/0.0/0.0/0.0 | 55.2/37.9/6.9/0.0 | 71.0/16.1/9.7/3.2 | ||
| GDS | NF/MiF/ModF/SF | n | 7/5/2/0 | 8/2/3/0 | 14/4/1/0 | 6/4/1/0 | 8/4/2/0 | 0/2/0/0 | 8/16/5/0 | 9/15/7/0 |
| % | 50.0/35.7/14.3/0.0 | 61.5/15.4/23.1/0.0 | 73.7/21.1/5.3/0.0 | 54.5/36.4/9.1/0.0 | 57.1/28.6/14.3/0.0 | 0.0/100/0.0/0.0 | 27.6/55.2/17.2/0.0 | 29.0/48.4/22.6/0.0 | ||
| Number of medications | NF/MiF/ModF/SF | n | 5/6/3/0 | 4/5/3/1 | 3/11/5/0 | 2/4/5/0 | 0/8/5/1 | 0/1/1/0 | 1/12/8/8 | 0/16/7/8 |
| % | 35.7/42.9/21.4/0.0 | 30.8/38.5/23.1/7.7 | 15.8/57.9/26.3/0.0 | 18.2/36.4/45.5/0.0 | 0.0/57.1/35.7/7.1 | 0.0/50.0/50.0/0.0 | 3.4/41.4/27.6/27.6 | 0.0/51.6/22.6/25.8 | ||
CABG, coronary artery bypass grafting; CORO, coronarography; F, females; HF, heart failure; M, males; MiF, mild frailty; ModF, moderate frailty; n, number; NF, not frail; PCI, percutaneous coronary intervention; SF, severe frailty; TUG, timed up-and-go test. Results are expressed as n or % (% within males or within females per CVD); * p < 0.05 association between level (severity) of frailty and sex per CVD.